Abstract
Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Current Diabetes Reviews
Title:Hyperglycemia to Nephropathy via Transforming Growth Factor Beta
Volume: 10 Issue: 3
Author(s): Mayuresh Sudamrao Garud and Yogesh Anant Kulkarni
Affiliation:
Keywords: AGE, GBM, glomerulosclerosis, PDGF, protein kinase C, VEGF.
Abstract: Nephropathy is one of the major complications of diabetes which further directs to end stage renal disease. Extensive work has been done to find out the mechanisms involved in pathogenesis of the DN. Now, many researchers have been convinced that almost all of the molecular mediators and intracellular signaling pathways involved in progression of diabetic nephropathy have involvement in transforming growth factor beta (TGF- β) at some stage.
In DN, hyperglycemia causes increase in the expression of TGF- β genes, TGF- β proteins and their receptors. Increased glucose level mediates these effects through activation of polyol pathway, protein kinase C pathway, hexosamine pathway, increases advanced glycation end products (AGE) and increases oxidative stress. Hyperglycemia also activates the TGF- β via activation of glucose transporters (GLUT), angiotensine II and platelet derived growth factor (PDGF). Activated TGF-β further leads to glomerular basement membrane (GBM) thickening and glomerulosclerosis through activation of connective tissue growth factor (CDGF) and vascular endothelial growth factor (VEGF).
We have discussed the progression of hyperglycemia to DN via TGF- β, whose schematic presentation may serve as an effective way to understand the mechanisms and to find out an effective way for the management of diabetic nephropathy.
Export Options
About this article
Cite this article as:
Garud Sudamrao Mayuresh and Kulkarni Anant Yogesh, Hyperglycemia to Nephropathy via Transforming Growth Factor Beta, Current Diabetes Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/1573399810666140606103645
DOI https://dx.doi.org/10.2174/1573399810666140606103645 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recommendations for the Treatment of Hypertension in Patients with DM: Critical Evaluation Based on Clinical Trials
Current Clinical Pharmacology Rational Targeting of the Urokinase Receptor (uPAR): Development of Antagonists and Non-Invasive Imaging Probes
Current Drug Targets Addressing Unmet Medical Needs in Type 1 Diabetes: A Review of Drugs Under Development
Current Diabetes Reviews Cardiovascular Disease: What's All the AGE/RAGE About?
Cardiovascular & Hematological Disorders-Drug Targets Chronic Exposure to Low-Level Cadmium in Diabetes: Role of Oxidative Stress and Comparison with Polychlorinated Biphenyls
Current Drug Targets Role of Renin-Angiotensin-Aldosterone System in Metabolic Syndrome and Obesity-related Hypertension
Current Hypertension Reviews Recent Developments in the Separation of Low Molecular Weight Heparin Anticoagulants
Current Medicinal Chemistry Ezetimibe Therapy for Dyslipidemia: An Update
Current Pharmaceutical Design Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Antiplatelet Treatment in Ischemic Stroke Treatment
Current Topics in Medicinal Chemistry Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Insight on the Pathogenesis of Diabetic Nephropathy from the Study of Podocyte and Mesangial Cell Biology
Current Diabetes Reviews Metabolomics and the Diagnosis of Human Diseases -A Guide to the Markers and Pathophysiological Pathways Affected
Current Medicinal Chemistry An Overview on Potential Neuroprotective Compounds for Management of Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Impact of Omega-3 Fatty Acids on Osteoporosis
Current Pharmaceutical Design Free Radicals Generated by Post-Prandial Oxidative Burst in the Early Alterations of Vascular Contractility
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) The Endocannabinoid System: A Promising Target for the Management of Type 2 Diabetes
Current Protein & Peptide Science Pharmacology of Rhein and Advancement in the Synthesis of Its Derivatives
Current Traditional Medicine Advanced Glycation End Products as Environmental Risk Factors for the Development of Type 1 Diabetes
Current Drug Targets IgA Nephropathy: Clinical Significance of Urinary Proteins/Polypeptides Characterization
Current Proteomics